NCI Community Oncology Research Program - Kansas City (NCORP-KC)
NCI Community Oncology Research Program - Kansas City (NCORP-KC)




GU Clinical Trials

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

 

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.



Prostate

ECOG-ACRIN EA8153 - "Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: the CHAARTED2 Trial"

CANCER TYPE: Prostate
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT03419234
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 02/22/2019 (22:18:45)

BRIEF DESCRIPTION

Prostate adenoca, progressive, soft tissue and/or bone mets, previous docetaxel, androgen deprivation and abiraterone and prednisone +/- cabazitaxel.






NRG-GU002 - "PHASE II-III TRIAL OF ADJUVANT RADIOTHERAPY AND ANDROGEN DEPRIVATION FOLLOWING RADICAL PROSTATECTOMY WITH OR WITHOUT ADJUVANT DOCETAXEL"

CANCER TYPE: Prostate
RESEARCH BASE: NRG
NCT NUMBER: NCT03070886
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
BRIEF DESCRIPTION

Post-prostatectomy, baseline Gleason ≥ 7, any pT, pN0 or pNX, no distant mets, adj. RT and androgen deprivation, with or without adj. docetaxel.






Renal

Alliance A031704 - "PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]"

CANCER TYPE: Renal
RESEARCH BASE: Alliance
NCT NUMBER: NCT03793166
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 05/23/2019 (18:08:50)

BRIEF DESCRIPTION

Stage IV, untreated renal cell carcinoma with clear cell component, nivolumab + ipilimumab, patients w/PD will be randomized to cabozantinib






ECOG-ACRIN EA8143 - "A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)"

CANCER TYPE: Renal
RESEARCH BASE: ECOG-ACRIN
NCT NUMBER: NCT03055013
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 06/11/2019 (16:57:50)

BRIEF DESCRIPTION

Clinical stage ≥ T2Nx RCC or TanyN+ RCC for which radical or partial nephrectomy is planned, nephrectomy w/wo Nivolumab.  DCP-001 Eligible






SWOG S1500 - "A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)

CANCER TYPE: Renal
RESEARCH BASE: SWOG
NCT NUMBER: NCT02761057
Protocol Summary: VIEW SUMMARY
Consent Form: VIEW CONSENT FORM
UPDATED ON 05/23/2019 (18:01:04)

BRIEF DESCRIPTION

Stage IV, type I or II papillary renal carcinoma, cabozantinib vs. crizotinib vs. savolitinib vs. sunitinib









  © 2013-2019 All Rights Reserved. Privacy Policy | Terms & Conditions
NCI Community Oncology Research Program - Kansas City (NCORP-KC)
Questions? Call: +1-913-948-5588 | Contact Us
4121 W. 83rd St., Suite 259 Prairie Village, KS 66208 USA